These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36883881)

  • 1. Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Durgam S; Edwards JB; Davis RE
    J Clin Psychiatry; 2023 Mar; 84(2):. PubMed ID: 36883881
    [No Abstract]   [Full Text] [Related]  

  • 2. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm.
    Citrome L; Du Y; Weiden PJ
    Neuropsychiatr Dis Treat; 2019; 15():2639-2646. PubMed ID: 31686823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
    Correll CU; Davis RE; Weingart M; Saillard J; O'Gorman C; Kane JM; Lieberman JA; Tamminga CA; Mates S; Vanover KE
    JAMA Psychiatry; 2020 Apr; 77(4):349-358. PubMed ID: 31913424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sertindole for schizophrenia.
    Lewis R; Bagnall AM; Leitner M
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD001715. PubMed ID: 16034864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Juday T; Frech F; Atkins N
    J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
    [No Abstract]   [Full Text] [Related]  

  • 9. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials.
    Kane JM; Durgam S; Satlin A; Vanover KE; Chen R; Davis R; Mates S
    Int Clin Psychopharmacol; 2021 Sep; 36(5):244-250. PubMed ID: 34054112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumateperone for the Treatment of Schizophrenia.
    Edinoff A; Wu N; deBoisblanc C; Feltner CO; Norder M; Tzoneva V; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Sep; 50(4):32-59. PubMed ID: 33012872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.
    Correll CU; Vanover KE; Davis RE; Chen R; Satlin A; Mates S
    Schizophr Res; 2021 Feb; 228():198-205. PubMed ID: 33453691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine for schizophrenia.
    Srisurapanont M; Maneeton B; Maneeton N
    Cochrane Database Syst Rev; 2004; 2004(2):CD000967. PubMed ID: 15106155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.
    Citrome L; Risinger R; Rajachandran L; Robison H
    Adv Ther; 2022 Oct; 39(10):4821-4835. PubMed ID: 36002761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    François C; Rowse GJ; Hewitt LA; Vo P; Hauser RA
    BMC Neurol; 2016 Aug; 16(1):143. PubMed ID: 27538531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; DiBernardo A; Singh J
    J Affect Disord; 2020 Jun; 271():228-238. PubMed ID: 32479321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.